GRCE

AI Memo

Grace Therapeutics

As of 2026-07-31/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Type A meeting minutes clarify the NDA remediation path • 2026-07-28

Expected move: +7%

Biggest risk

The FDA CRL remains unresolved. cGMP remediation, facility reinspection, second-source technology transfer, additional studies, timing uncertainty, and potential financing needs leave the thesis highly execution- and dilution-sensitive.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The Type A meeting record removes a potentially more serious clinical-data concern: FDA did not identify clinical safety or efficacy deficiencies or request additional clinical data. If Grace executes the manufacturing and non-clinical remediation and resubmits successfully, GTx-104 could support substantial upside.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-31

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

GTx-104 NDA resubmission and potential approval
The Type A meeting record removes a potentially more serious clinical-data concern: FDA did not identify clinical safety or efficacy deficiencies or request additional clinical data.
If Grace executes the manufacturing and non-clinical remediation and resubmits successfully, GTx-104 could support substantial upside.

BearKey bullets

Additional capital may be required, creating dilution and financing-risk exposure.
Analyst coverage, recent-news coverage, social context, and post-update target or estimate revisions are unavailable.
FDA CRL remediation remains outstanding, including cGMP, leachables, and toxicology work.

WatchKey bullets

Type A meeting minutes clarify the NDA remediation path

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $2 (p=50%)

Bull/Bear spread: +180% / -49%

Vs latest close: Bull +180% · Base +7% · Bear -49%

Scenario probabilities

Bull Target: $6 (p=25%)Base Target: $2 (p=50%)Bear Target: $1 (p=25%)

Commentary

The latest primary company update is constructive on regulatory clarity but does not establish approval or a dated resubmission. The deterministic prior is negative, while the new Type A minutes improve evidence quality without removing execution risk. No analyst revisions, target changes, market-reaction attribution, or social coverage are available; confidence remains limited despite the strong primary-source context.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

GTx-104 NDA resubmission and potential approval

Scenarios

Bull Target (Scenario probability)

$6 / p=25% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $2 as of 2026-08-05

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +180% · Base +7% · Bear -49%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-28
Type A meeting minutes clarify the NDA remediation path
Grace reported that FDA meeting minutes identified no clinical safety or efficacy deficiencies and requested no additional clinical data. Remaining work concerns cGMP remediation, leachables data, toxicology assessments, and a dual-source manufacturing strategy. [#SEC-8K-2026-07-28] [#8-K-2026-07-28]
Prob 75.00% • Move 15.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

GTx-104 NDA resubmission and potential approval
2027-07-31
The company plans to address the FDA’s CRL items and pursue resubmission, but no resubmission date is disclosed. Timing depends on manufacturing remediation, a potential second U.S. manufacturing source, additional non-clinical work, and FDA review. [#SEC-8K-2026-07-28] [#SEC-10K-2026-06-18]
Prob 45% • Move 45% • Priced-in 35%

Risks

Additional capital may be required, creating dilution and financing-risk exposure.
Analyst coverage, recent-news coverage, social context, and post-update target or estimate revisions are unavailable.
FDA CRL remediation remains outstanding, including cGMP, leachables, and toxicology work.
No dated NDA resubmission timetable is disclosed; manufacturing reinspection and second-source qualification may delay review.
Small-cap biotech liquidity and event volatility are high.

Peers

Symbol	Summary
CRVO	Same-sector, similar-market-cap comparator; the packet provides no direct therapeutic or clinical overlap, so peer valuation use is weak.
ESLA	Same-sector, similar-market-cap comparator; useful mainly for small-cap biotech event volatility, not as a close operating peer.
IXHL	Same-sector, similar-market-cap comparator with limited direct comparability based on the available packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

AI Stock Memo: GRCE - Grace Therapeutics - RankAlpha